BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

487 related articles for article (PubMed ID: 19272650)

  • 21. An observational study on bloodstream extended-spectrum beta-lactamase infection in critical care unit: incidence, risk factors and its impact on outcome.
    Nasa P; Juneja D; Singh O; Dang R; Singh A
    Eur J Intern Med; 2012 Mar; 23(2):192-5. PubMed ID: 22284253
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Emergence of extended-spectrum β-lactamase-producing escherichia coli as a cause of community-onset bacteremia in South Korea: risk factors and clinical outcomes.
    Park SH; Choi SM; Lee DG; Kim J; Choi JH; Kim SH; Kwon JC; Yoo JH
    Microb Drug Resist; 2011 Dec; 17(4):537-44. PubMed ID: 21875342
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bacteremia due to extended-spectrum beta-lactamase-producing Enterobacteriaceae other than Escherichia coli and Klebsiella.
    Huang SS; Lee MH; Leu HS
    J Microbiol Immunol Infect; 2006 Dec; 39(6):496-502. PubMed ID: 17164953
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incidence of acute prostatitis caused by extended-spectrum beta-lactamase-producing Escherichia coli after transrectal prostate biopsy.
    Ozden E; Bostanci Y; Yakupoglu KY; Akdeniz E; Yilmaz AF; Tulek N; Sarikaya S
    Urology; 2009 Jul; 74(1):119-23. PubMed ID: 19464043
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical implications, risk factors and mortality following community-onset bacteremia caused by extended-spectrum β-lactamase (ESBL) and non-ESBL producing Escherichia coli.
    Hsieh CJ; Shen YH; Hwang KP
    J Microbiol Immunol Infect; 2010 Jun; 43(3):240-8. PubMed ID: 21291853
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of antibiotic resistance and of adequate empirical antibiotic treatment in the prognosis of patients with Escherichia coli bacteraemia.
    Peralta G; Sánchez MB; Garrido JC; De Benito I; Cano ME; Martínez-Martínez L; Roiz MP
    J Antimicrob Chemother; 2007 Oct; 60(4):855-63. PubMed ID: 17644532
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence and antimicrobial resistance patterns of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolated from blood cultures in an Istanbul University Hospital.
    Koksal F; Ak K; Kucukbasmaci O; Samasti M
    Chemotherapy; 2009; 55(4):293-7. PubMed ID: 19521075
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical and economic impact of bacteremia with extended- spectrum-beta-lactamase-producing Enterobacteriaceae.
    Schwaber MJ; Navon-Venezia S; Kaye KS; Ben-Ami R; Schwartz D; Carmeli Y
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1257-62. PubMed ID: 16569837
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epidemiology and clinical outcomes of bloodstream infections caused by extended-spectrum β-lactamase-producing Escherichia coli in patients with cancer.
    Ha YE; Kang CI; Cha MK; Park SY; Wi YM; Chung DR; Peck KR; Lee NY; Song JH
    Int J Antimicrob Agents; 2013 Nov; 42(5):403-9. PubMed ID: 24071027
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incidence of fluoroquinolone-resistant and extended-spectrum β-lactamase-producing Escherichia coli at a comprehensive cancer center in the United States.
    Bhusal Y; Mihu CN; Tarrand JJ; Rolston KV
    Chemotherapy; 2011; 57(4):335-8. PubMed ID: 21912115
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Extended spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae bacteremia. Risk factors and outcome in the eastern region of Saudi Arabia.
    Memon JI; Rehmani RS; Ahmed MU; Elgendy AM; Nizami IY
    Saudi Med J; 2009 Jun; 30(6):803-8. PubMed ID: 19526164
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prior use of carbapenems may be a significant risk factor for extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella spp. in patients with bacteraemia.
    Martínez JA; Aguilar J; Almela M; Marco F; Soriano A; López F; Balasso V; Pozo L; Mensa J
    J Antimicrob Chemother; 2006 Nov; 58(5):1082-5. PubMed ID: 16950822
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association between fluoroquinolone resistance and mortality in Escherichia coli and Klebsiella pneumoniae infections: the role of inadequate empirical antimicrobial therapy.
    Lautenbach E; Metlay JP; Bilker WB; Edelstein PH; Fishman NO
    Clin Infect Dis; 2005 Oct; 41(7):923-9. PubMed ID: 16142655
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk factors and treatment outcomes of community-onset bacteraemia caused by extended-spectrum beta-lactamase-producing Escherichia coli.
    Kang CI; Song JH; Chung DR; Peck KR; Ko KS; Yeom JS; Ki HK; Son JS; Lee SS; Kim YS; Jung SI; Kim SW; Chang HH; Ryu SY; Kwon KT; Lee H; Moon C; Shin SY;
    Int J Antimicrob Agents; 2010 Sep; 36(3):284-7. PubMed ID: 20580534
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.
    Rodríguez-Baño J; Alcalá JC; Cisneros JM; Grill F; Oliver A; Horcajada JP; Tórtola T; Mirelis B; Navarro G; Cuenca M; Esteve M; Peña C; Llanos AC; Cantón R; Pascual A
    Arch Intern Med; 2008 Sep; 168(17):1897-902. PubMed ID: 18809817
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Correlation between in vitro bacterial growth velocity of blood of patients with clinical parameters and prognosis in patients with Escherichia coli bacteremia].
    Bo SN; Ning YZ; Zhu X; Yao GQ
    Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2010 Sep; 22(9):533-6. PubMed ID: 20854732
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical outcome of extended-spectrum beta-lactamase-producing Escherichia coli bacteremia in an area with high endemicity.
    To KK; Lo WU; Chan JF; Tse H; Cheng VC; Ho PL
    Int J Infect Dis; 2013 Feb; 17(2):e120-4. PubMed ID: 23098812
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Detection of drug-resistant Escherichia coli in patients with complicated cystitis: analysis of risk factors.
    Shigehara K; Uchibayashi T; Maeda E; Namiki M
    Int J Urol; 2009 Oct; 16(10):808-12. PubMed ID: 19659550
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended-spectrum beta-lactamase-producing enterobacteriaceae: variability by site of infection.
    Hyle EP; Lipworth AD; Zaoutis TE; Nachamkin I; Bilker WB; Lautenbach E
    Arch Intern Med; 2005 Jun; 165(12):1375-80. PubMed ID: 15983286
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence of extended-spectrum beta-lactamase-producing Escherichia coli in a tertiary care hospital in Tehran, Iran.
    Mehrgan H; Rahbar M
    Int J Antimicrob Agents; 2008 Feb; 31(2):147-51. PubMed ID: 18060745
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.